Vital Therapies reported $-21435000 in Operating Profit for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Biomarin Pharmaceutical BMRN:US $ 137.33M 203.21M
Dynavax Technologies DVAX:US $ 30.76M 49.95M
Enanta Pharmaceuticals ENTA:US $ -33.85M 3.44M
Epizyme EPZM:US $ -50926000 360K
Insmed INSM:US $ -89833000 9.24M
Intercept Pharmaceuticals ICPT:US $ -10.27M 10.59M
Mirati Therapeutics MRTX:US $ -184.22M 12.86M
Orasure Technologies OSUR:US $ -15.98M 6.61M
Quidel QDEL:US $ 620.66M 243.93M
Regulus Therapeutics RGLS:US $ -6.57M 0.39M
Revance Therapeutics RVNC:US $ -62221000 617K
Ultragenyx Pharmaceutical RARE:US $ -136.63M 34.07M
United Therapeutics UTHR:US $ 286.3M 116.5M
Vital Therapies VTL:US $ -21.44M 0.29M
Xoma XOMA:US $ -2065000 32.43M